Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.

Although cAMP is an important second messenger that plays a pivotal role in the regulation of platelet aggregation and dilatation of blood vessels, little is known about the action of cAMP on the growth of vascular smooth muscle cells (VSMCs). Thus, we initially studied the effects of cAMP accumulation by using various cAMP stimulants, including a phosphodiesterase type 3 inhibitor (cilostazol) on human aortic VSMC growth. Accumulation of cAMP inhibited the platelet-derived growth factor (PDGF)-stimulated VSMC growth in a dose-dependent manner (P<0.01), whereas PDGF significantly stimulated the growth of human VSMCs. Thus, we focused on the role of cell cycle regulatory genes, especially on a negative regulator, an anti-oncogene, p53. The protein of p53 was potentiated by cilostazol as well as forskolin and 8-bromo-cAMP, whereas PDGF decreased p53 expression. Upregulation of p53 protein by cAMP was further confirmed by the observation that the decrease in p21, a p53-inducible protein, by PDGF was significantly attenuated by cilostazol in a dose-dependent manner (P<0.01). These results revealed that accumulation of cAMP inhibited VSMC proliferation, which was at least in part due to an increase in p53-p21 expression. Because p53 and p21 have been reported to induce apoptosis, we examined apoptotic cells for cAMP accumulation. Incubation of VSMCs with cilostazol resulted in a significant increase in apoptotic cells in a dose-dependent manner compared with vehicle treatment as assessed by nuclear chromatic morphology (P<0.01); forskolin also stimulated apoptotic cells. Consistent with nuclear staining, DNA fragmentation in VSMCs treated with forskolin as well as 8-bromo-cAMP and cilostazol was significantly increased compared with DNA fragmentation in VSMCs treated with vehicle, whereas PDGF significantly decreased the rate of DNA fragmentation (P<0.01). Overall, these results demonstrated that cAMP inhibited the proliferation of human aortic VSMCs, accompanied by p53-p21-mediated apoptosis. Analogues of cAMP that have direct inhibitory effects on VSMC proliferation can be considered as potential antiproliferative drugs against VSMC growth.

[1]  M. Aoki,et al.  Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell growth. , 1999, Hypertension.

[2]  E. Tsuchikane,et al.  Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. , 1999, Circulation.

[3]  P. Sassone-Corsi,et al.  Signaling routes to CREM and CREB: plasticity in transcriptional activation. , 1999, Trends in biochemical sciences.

[4]  D. Dawson,et al.  Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. , 1998, Circulation.

[5]  M. Aoki,et al.  Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene , 1998, Gene Therapy.

[6]  M. Aoki,et al.  Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis. , 1998, Hypertension.

[7]  G. Condorelli,et al.  Activation of cAMP–PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury , 1997, Nature Medicine.

[8]  T. Iwasaka,et al.  Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. , 1997, The American journal of cardiology.

[9]  M. Aoki,et al.  Serum deprivation-induced apoptosis accompanied by up-regulation of p53 and bax in human aortic vascular smooth muscle cells. , 1997, Heart and vessels.

[10]  A. Amsterdam,et al.  Cross-talk between cAMP and p53-generated signals in induction of differentiation and apoptosis in steroidogenic granulosa cells , 1996, Steroids.

[11]  G. Kou,et al.  Human Cytomegalovirus Immediate-Early Protein IE2 Tethers a Transcriptional Repression Domain to p53 (*) , 1996, The Journal of Biological Chemistry.

[12]  T. Horio,et al.  Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. , 1995, Circulation research.

[13]  E. Krebs,et al.  Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction , 1995, The Journal of cell biology.

[14]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Isner,et al.  Apoptosis in human atherosclerosis and restenosis. , 1995, Circulation.

[16]  M. Oren,et al.  cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. , 1995, Experimental cell research.

[17]  H. Kamiya,et al.  Fas antigen and bcl-2 expression on lymphocytes cultured with cytomegalovirus and varicella-zoster virus antigen. , 1995, Cellular immunology.

[18]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[19]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[20]  M. Sakon,et al.  Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol. , 1995, Pharmacological research.

[21]  S. L. Brown,et al.  Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. , 1994, Cardiovascular research.

[22]  J. Beavo,et al.  Multiple cyclic nucleotide phosphodiesterases. , 1994, Molecular pharmacology.

[23]  S. Lowe,et al.  p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.

[24]  M. Leon,et al.  Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. , 1994, Science.

[25]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[26]  T. Ogihara,et al.  Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.

[27]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[28]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[29]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Ishiyama,et al.  A New Sulfonated Tetrazolium Salt That Produces a Highly Water-Soluble Formazan Dye , 1993 .

[31]  M. Lanotte,et al.  Antiapoptotic effect of heterozygously expressed mutant RI (Ala336-->Asp) subunit of cAMP kinase I in a rat leukemia cell line. , 1993, The Journal of biological chemistry.

[32]  T. Ogihara,et al.  Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. , 1993, Artery.

[33]  P. Bonin,et al.  Growth factor-induced modulation of endothelin-1 binding to human smooth-muscle cells. , 1993, Journal of cardiovascular pharmacology.

[34]  N. Morisaki,et al.  Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. , 1992, Journal of Biological Chemistry.

[35]  G. Hassall,et al.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. , 1992, Biochemical pharmacology.

[36]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[37]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[38]  Y. Goda,et al.  The mutagenic constituents of Rubia tinctorum. , 1992, Chemical & pharmaceutical bulletin.

[39]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Hidaka,et al.  Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. , 1992, Advances in second messenger and phosphoprotein research.

[41]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[42]  M. Montminy,et al.  Induction of a cyclic AMP-responsive gene in living cells requires the nuclear factor CREB , 1991, Molecular and cellular biology.

[43]  M. Lampugnani,et al.  Endothelial cell motility, integrin receptor clustering, and microfilament organization are inhibited by agents that increase intracellular cAMP. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[44]  Kortaro Tanaka,et al.  Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. , 1989, Stroke.

[45]  M. Hagiwara,et al.  Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. , 1988, Pharmacology.

[46]  A. Olsson,et al.  Prostaglandin E1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. , 1984, Atherosclerosis.

[47]  P. Libby,et al.  Culture of quiescent arterial smooth muscle cells in a defined serum‐free medium , 1983, Journal of cellular physiology.

[48]  Peter J. Smith.  Earthquakes without precursors? , 1975, Nature.